GLP1R and type 2 diabetes mellitus: Due to its role in insulin secretion, the GLP-1 receptor has received significant attention as a possible therapeutic target for treating type 2 diabetes, resulting in the approval of three peptide analogues of GLP-1 (liraglutide, exenatide, and lixisenatide) for clinical use.